This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Clinicalpackaging and labelling follow stringently controlled procedures and high-standard quality control measures to assure the safety and functionality of investigational medicinal products, during their storage, distribution, and use. Finding the best clinicaltrialpackaging services providers.
According to GlobalData’s clinicaltrials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone. Cell and gene therapies are not your typical clinicalsupply chain. The requirements When handling personalised medicines, time is of the essence.
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinicalsupply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01.
Planning on running clinicaltrials in Japan? How can you reliably supply these studies? Discover Catalent’s clinicalsupplypackaging facility in Shiga, Japan.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Late integration of RTSM means it inherits decisions made upstream in the trial process. Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful.
Late integration of RTSM means it inherits decisions made upstream in the trial process. Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful.
Late integration of RTSM means it inherits decisions made upstream in the trial process. Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful.
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinicalsupply and commercial launch. at the BioProcess International Theater.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Late integration of RTSM means it inherits decisions made upstream in the trial process. Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful.
Randomization and TrialSupply Management (RTSM) play a pivotal role in the successful execution of clinicaltrials. As the complexity of clinicaltrials continues to increase, especially with the rise of multi-center, adaptive, and decentralized trials, the need for robust RTSM systems has become more critical than ever.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content